Articles tagged with Fibrosis
A groundbreaking study published in Science Advances has identified five unique cell types associated with lung fibrosis, including a pro-fibrotic epithelial cell that drives the disease. The research also reveals high plasticity in lung cells, allowing them to transform into different types under certain conditions.
A novel microbiome-based diagnostic tool has been developed to quickly and inexpensively identify liver fibrosis and cirrhosis in patients. The non-invasive method analyzes patient stool samples and achieves an accuracy of over 90% in diagnosing cirrhosis, with potential implications for improving treatment outcomes.
A study by Massachusetts General Hospital researchers found that a protein called AP-2 beta induces expression of KCTD1, which triggers kidney structure differentiation. The discovery could lead to therapeutic approaches to block reactivation of beta-catenin in the adult kidney to inhibit renal fibrosis.
Researchers discover e-cigarette liquid can cause lung tissue repair process to go haywire, leading to scarring. Inhibiting a certain nicotinic receptor may help promote cell death and slow scar formation in affected individuals.
Researchers discovered that the loss of NEDD4-2 protein leads to impaired mucociliary clearance and dysregulation of the TGF? signaling pathway, contributing to pulmonary fibrosis progression. The study provides a novel animal model for IPF research, enabling further investigation of disease mechanisms and development of new treatments.
Research reveals TGF-β-driven reduction of cytoglobin (CYGB) in HSCs leads to oxidative DNA damage and liver fibrosis in NASH. CYGB has a protective effect on hepatic parenchymal cells by scavenging hydroxyl radicals.
Researchers have found a way to halt and reverse muscle fibrosis caused by overuse injuries in animal studies. The discovery uses the drug FG-3019 to block protein CCN2, which promotes connective tissue growth, leading to significant improvements in muscle strength.
A recent study published in Immunity identified the protein Rbm7 as a key player in the development of tissue fibrosis. The researchers found that Rbm7 induces cell death after tissue injury, leading to the recruitment of immune cells that form scar tissue.
Researchers at University of Illinois and Mie University discover salt-loving bacteria secret a peptide that rapidly kills lung cells, leading to acute exacerbation. The finding offers a potential new target for treating pulmonary fibrosis, a disease affecting millions worldwide.
A new technology has been used to investigate the cellular processes involved in liver fibrosis development, revealing key genes and cell types that correlate with fibrogenesis. The findings have potential applications for diagnostic tools and therapies.
Researchers found that liver fibrosis is tied to a specific type of heart failure, known as preserved ejection fraction heart failure (HFpEF), which affects people with and without HIV and hepatitis C. The study suggests that preventing liver fibrosis may be crucial in reducing the risk of HFpEF.
A new study from North Carolina State University found that lung stem cell secretions delivered via nebulizer can help repair lung injuries due to multiple types of pulmonary fibrosis in mice and rats. The treatment resulted in a nearly 50% reduction of fibrosis compared to mesenchymal stem cells counterparts.
Researchers have identified three genes linked to idiopathic pulmonary fibrosis (IPF), a devastating lung disease. The discovery provides potential targets for new drugs and may lead to improved treatments.
A team of Yale researchers has discovered a way to reverse type-2 diabetes and liver fibrosis in mice, highlighting the potential for targeting TET3 protein. The studies, published in Cell Reports and Nature Communications, also suggest that TET3 plays a role in fibrosis development and may be a key target for treatment.
Researchers at UC San Diego School of Medicine identified genetic switches that determine whether or not liver cells produce collagen, leading to a potential therapeutic target for liver fibrosis. By manipulating these transcription factors, liver fibrosis progression can be addressed.
Scientists discovered that magnetic nanoparticles can target and treat liver fibrosis by delivering drugs to the affected tissue, reducing inflammation and improving liver function. This new approach offers a potential solution for treating this fatal illness with improved patient outcomes.
A UK study found that over 20% of young adults have fatty liver disease, with those who are overweight or obese at greatest risk. The research highlights the need for improved liver health awareness and management among this age group.
A study found that people who sleep 4 hours or less double their risk of pulmonary fibrosis and those who sleep 11 hours or more triple their chance. The researchers attribute this to the body clock and suggest targeting it as a potential target for treating the disease.
Researchers propose using transient elastography as a screening method for detecting liver fibrosis in primary care. The study shows that this approach is highly cost-effective and can improve patient outcomes, with a 12% probability of cost saving.
A team led by Dr. Brigitte Gomperts developed a 'scar in a dish' model that accurately replicates progressive scarring in human organs, enabling the identification of a drug candidate that halted or reversed fibrosis in animal models.
A study suggests that monocyte-derived macrophages can induce lung fibrosis without prior alveolar epithelial cell injury. The research found increased flux through the mevalonate pathway in bronchoalveolar cells from IPF patients, which exacerbates fibrosis.
Researchers at Mayo Clinic have identified a way to slow and reverse fibrosis by targeting a dopamine receptor, which blocks the growth of scar-forming cells. The approach reversed fibrotic processes in lung and liver models, offering a new treatment concept for fibrotic diseases.
Researchers at Georgia State University have developed a protein-based contrast agent that can detect early-stage liver diseases, including liver fibrosis, with high accuracy and sensitivity. The new method uses a lower dosage of contrast metal gadolinium, reducing the risk of metal toxicity and enabling earlier diagnosis and treatment.
Researchers have identified a genetic mutation in the SFTPA1 gene that causes idiopathic pulmonary fibrosis (IPF), a progressive lung disease characterized by scar tissue buildup. Inhibiting necroptosis, a cell death pathway, could be a new therapeutic approach to treating IPF.
University of Delaware Professor April Kloxin wins NIH Director's New Innovator Award to develop synthetic models of idiopathic pulmonary fibrosis, a fatal disease affecting over 3 million people globally. Her research aims to uncover insights into the underlying causes and potential treatments for lung fibrosis.
A laboratory study found that fibrosis, a natural stiffening of the ovaries, occurs with age and may be linked to ovarian cancer. Metformin, a diabetes drug, was shown to halt this process in some cases.
Researchers at Temple University Health System have identified a novel signaling pathway that regulates fibrosis, a condition characterized by the formation of excessive scar tissue. By targeting this pathway, they hope to develop new treatments for fibrotic diseases, which can lead to serious health complications.
A recent study published in the New England Journal of Medicine found that nintedanib slows the progression of a broad range of scarring lung diseases. The medication was shown to be effective in patients with progressive fibrosing interstitial lung disease, regardless of the underlying cause or pattern of lung fibrosis.
Researchers found that blocking interleukin-11 protein with therapeutic antibodies can reverse lung fibrosis in a mouse model. This discovery holds promise for treating idiopathic pulmonary fibrosis (IPF), a life-threatening lung disease. Clinical trials are expected to begin by 2021.
A research team at the University of Colorado School of Medicine has identified BRD4 as a central regulator of cardiac fibroblast activation. Chemical inhibitors of BRD4 potently block cardiac fibroblast activation, providing a potential therapeutic target for heart failure treatment.
Researchers at Monash University have discovered that receptors can communicate and interact, affecting the therapeutic actions of relaxin. This finding has implications for clinical trials involving relaxin and other drugs acting on these receptors.
Researchers at the University of Trento have developed a genome editing strategy to permanently correct two types of mutations that cause cystic fibrosis. The 'SpliceFix' technique uses Crispr-Cas to edit patient-derived organoids, showing high precision and efficacy.
Michelle Long, MD, MSc, assistant professor of medicine at Boston University School of Medicine, has been awarded a three-year, $495,000 Doris Duke Clinical Scientist Development Award to investigate the relationship between physical activity and NAFLD. The study aims to identify biomarkers of early disease and risk for progression.
A recent study published in PLoS One found a link between the gene AEBP1 and severe liver damage, specifically nonalcoholic steatohepatitis. The research suggests that AEBP1 regulates a network of genes related to fibrosis, which could lead to new therapeutic targets for treating liver disease.
Lung scarring can lead to pulmonary fibrosis and life-threatening complications. Researchers found increased MMP activity in lung tissue affected by Hermansky-Pudlak syndrome, suggesting a new link for diagnosis and treatment.
Researchers at St. Jude Children's Research Hospital have discovered an association between a mutation in the NEU1 gene and fibrotic conditions, including idiopathic pulmonary fibrosis. The study found that mice lacking the Neu1 gene developed muscle atrophy due to excessive connective tissue production.
MIT researchers have created a novel way to encapsulate islet cells, which they are developing as a possible treatment for patients with type 1 diabetes. The crystallized drug formulation prevents immune system rejection and allows the device to function for more than a year.
Researchers identified several potential therapeutic targets for Alport syndrome, including bardoxolone and anti-miRNA21. The disease is characterized by progressive kidney damage and proteinuria, and current treatments are primarily aimed at slowing disease progression rather than halting it.
Researchers at Georgia State University have developed a non-invasive method for detecting liver fibrosis using machine-learning algorithms and ultrasound scans. This technology has the potential to improve early diagnosis and treatment of liver diseases, which affect millions worldwide.
A joint ATS and European Respiratory Society statement reveals that occupational hazards contribute to over 1 in 10 cases of non-cancerous lung diseases, including asthma and COPD. The study estimates the burden of these conditions, highlighting a need for policy makers to prioritize prevention among working women and men worldwide.
Researchers at Cincinnati Children's Hospital Medical Center develop human liver organoids that accurately mimic key features of fatal liver diseases. The study reveals molecular secrets of deadly ailments and tests a potential therapy for Wolman disease, reversing an often-fatal childhood condition.
A study using praliciguat to stimulate soluble guanylate cyclase found that it can inhibit inflammation and fibrosis in liver cells, suggesting a potential therapy for nonalcoholic steatohepatitis. The results also indicate that praliciguat may suppress stellate cell fibrotic transformation.
Researchers developed a capsule-shaped photoacoustic imaging endoscope to examine intestinal changes in Crohn's disease. The device can differentiate between inflammatory and fibrotic strictures, allowing for more targeted treatment and potentially reducing adverse effects. This technology could also provide real-time diagnostic inform...
Researchers have discovered a potential new treatment for renal fibrosis by selectively activating AT1 receptors on T cells, which may help limit scar formation in the kidney. The study found that activating these receptors mitigates renal fibrogenesis by inhibiting Th1 differentiation and renal accumulation of pro-fibrotic macrophages.
A study of over 4,000 young adults in the UK found that nearly 20% had nonalcoholic fatty liver disease, and one in 40 had advanced fibrosis. The condition is linked to obesity, diabetes, and hyperlipidaemia, highlighting the need for greater public health awareness.
Researchers found that serum AKR1B10 levels were significantly associated with advanced liver fibrosis stages, particularly stage 4. The protein's origin was confirmed via immunohistochemical staining, and its combination with WFA(+)-M2BP showed high sensitivity and specificity for predicting NASH fibrosis and life-threatening events.
The Phase 3 REGENERATE study confirms obeticholic acid's effectiveness in treating NASH with liver fibrosis, improving fibrosis in almost one-quarter of recipients. The treatment also shows significant improvements in other histological markers of NASH, including lobular inflammation and hepatocellular ballooning.
The ATS Foundation/Boehringer Ingelheim Pharmaceuticals, Inc. Research Fellowship in Idiopathic Pulmonary Fibrosis aims to advance understanding of the disease through single cell transcriptomic analysis.
A new study from The Westmead Institute for Medical Research identified a genetic variant associated with liver fibrosis in chronic hepatitis C patients. This finding is crucial for preventing health complications and reducing the number of patients requiring liver transplants.
Researchers at VUMC and TGen are studying Idiopathic Pulmonary Fibrosis (IPF), a progressive and irreversible lung disease affecting 50,000 Americans annually. The grants will help identify specific gene expression changes driving the disease, potentially leading to earlier diagnosis and more effective treatments.
A study found that a protein associated with cancer growth is linked to idiopathic pulmonary fibrosis, a chronic and progressive lung condition. Introducing normal cells to inhibit the protein PD-L1 may reduce disease severity in laboratory mice and human tissue samples.
Researchers discovered that inhibiting the cancer-causing protein EZH2 can correct increased fibrosis and abnormal blood vessel function in scleroderma patients. This breakthrough suggests that existing EZH2 inhibitors could be repurposed to treat scleroderma, offering new hope for this currently incurable disease.
Fibrosis, a major complication of butterfly syndrome, is driven by the protein TSP1 and its activation of TGF-beta signaling. Researchers have identified a potential treatment by inhibiting TSP1, reducing fibrosis in tissue-engineered models.
A molecular network controlling connective tissue deposition has been decrypted, revealing a key protein PU.1 that causes pathological scarring. Inhibiting PU.1 may provide a new way to treat fibrotic diseases such as systemic sclerosis and idiopathic pulmonary fibrosis.
In connective tissue diseases, excessive activation of connective tissue cells leads to hardening and scarring within organs. The discovery of the protein PU.1 reveals a molecular mechanism responsible for ongoing activation of these cells, leading to fibrotic diseases.
A new study identifies key factors involved in cell cycle arrest and illuminates a novel intracellular structure, paving the way for new therapeutic targets to treat kidney fibrosis. The research team found that blocking the formation of TASCCs reduced the severity of kidney fibrotic disease progression in preclinical models.
A new study published in Nature Immunology has identified a new type of immune cell that infiltrates lung tissue and initiates fibrosis in idiopathic pulmonary fibrosis (IPF). The researchers were able to prevent fibrosis in mouse models by targeting these cells for destruction, which may lead to new treatments for this terminal illness.
A team of researchers has discovered a potential method to treat radiation-induced skin fibrosis by manipulating metabolism. They found that metabolic abnormalities are a key factor in the development of this condition, and identified several compounds and cell therapy techniques that may help alleviate its symptoms.
A nurse-led specialist clinic in GP surgeries has been shown to diagnose twice as many cases of liver disease than usual care. Simple tests, such as liver stiffness measurements and blood samples, detected nearly half of the patients as having some form of liver disease, including cirrhosis and fatty liver disease.
Researchers at Medical University of South Carolina identify insulin-like growth factor-binding protein 5 (IGFBP-5) as a potential therapeutic target for lung fibrosis. The protein promotes fibrosis by turning on profibrotic genes and increasing levels of profibrotic factors.